Merck and Co. Revenue and Competitors
Estimated Revenue & Valuation
- Merck and Co.'s estimated annual revenue is currently $52.6B per year.
- Merck and Co.'s estimated revenue per employee is $705,341
- Merck and Co.'s total funding is $5.6M.
- Merck and Co.'s current valuation is $205.6B. (January 2022)
Employee Data
- Merck and Co. has 74588 Employees.
- Merck and Co. grew their employee count by 3% last year.
Merck and Co.'s People
| Name | Title | Email/Phone |
|---|---|---|
1 | Coordinator, Office the CEO | Reveal Email/Phone |
2 | Chairman and CEO | Reveal Email/Phone |
3 | Director, Strategic Planning, Office the CEO | Reveal Email/Phone |
4 | Chief Marketing Officer Vaccines and Pharma Latin America Region | Reveal Email/Phone |
5 | VP | Reveal Email/Phone |
6 | Chief Staff to AVP Commercial AI Capabilities | Reveal Email/Phone |
7 | VP | Reveal Email/Phone |
8 | Lead Associate to VP, Discovery Biology-Cardiometabolic Disease, MRL SSF Site Lead | Reveal Email/Phone |
9 | Associate VP | Reveal Email/Phone |
10 | Associate VP, Merck Research Quality | Reveal Email/Phone |
Merck and Co. Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8343.5M | 41510 | 9% | N/A | N/A |
What Is Merck and Co.?
Merck is a leading research-driven pharmaceutical products and services company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck-Medco manages pharmacy benefits for employers, insurers and other plan sponsors, encouraging the appropriate use of medicines and providing disease management programs. Through these complementary capabilities, Merck works to improve quality of life and contain overall health-care costs
keywords:N/A
$5.6M
Total Funding
74588
Number of Employees
$52.6B
Revenue (est)
3%
Employee Growth %
$205.6B
Valuation
N/A
Accelerator
Merck and Co. News
Merck's call is scheduled for 8 a.m. on Thursday. Finally, Gilead shares are down 15% this year. Analysts expect EPS of $1.80, according to...
Romanelli returns to Merck after serving as chief executive officer of JiXing Pharmaceuticals, a China-based biopharmaceutical company, since...
Chutes & LaddersRomanelli returns to Merck to lead international human health team after brief CEO stint. By Max Bayer Apr 22, 2022 06:30am.
Global health care company Merck (NYSE:MRK), is to acquire* Afferent Pharmaceuticals, a San Mateo, CA-based pharmaceutical company that develops therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions, for up to $1.25 billion. Founde ...